Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis

Wafaa M. El-Sadr, David C. Perlman, John P. Matts, Eileen T. Nelson, David L. Cohn, Nadim Salomon, Margaret Olibrice, Frantz Medard, Keith D. Chirgwin, Donna Mildvan, Brenda E. Jones, Edward E. Telzak, Oscar Klein, Leonid Heifets, Richard Hafner

Research output: Contribution to journalArticlepeer-review

123 Scopus citations

Abstract

This study examined whether adding levofloxacin to a standard four- drug regimen improved the 8-week culture response and compared effectiveness of 9 versus 6 months of intermittent therapy for human immunodeficiency virus-related pansusceptible pulmonary tuberculosis. Patients were randomized to receive either four or five drugs, the fifth being levofloxacin. Patients who completed induction therapy were randomized to complete 9 versus 6 months of intermittent therapy with isoniazid and rifampin. In the randomized induction phase, 97.3% of patients in the four- drug group and 95.8% in the five-drug group had sputum culture conversion at 8 weeks (P = 1.00). In the continuation phase, one patient (2%) assigned to 9 months and two patients (3.9%) assigned to 6 months of therapy had treatment failure/relapse (P = 1.00). In conclusion, this study showed that levofloxacin added no benefit to a highly effective, largely intermittent, four-drug induction regimen. Both 9 and 6 months of intermittent therapy were associated with low treatment failure/relapse rates.

Original languageEnglish
Pages (from-to)1148-1158
Number of pages11
JournalClinical Infectious Diseases
Volume26
Issue number5
DOIs
StatePublished - 1998

Fingerprint

Dive into the research topics of 'Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis'. Together they form a unique fingerprint.

Cite this